e-learning
resources
ERJ
2004
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The yin and the yang of p27Kip1 as a target for cancer therapy
Eymin B., Brambilla E.
Source:
Eur Respir J 2004; 23: 663-664
Journal Issue:
May
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Eymin B., Brambilla E.. The yin and the yang of p27Kip1 as a target for cancer therapy. Eur Respir J 2004; 23: 663-664
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
The yin and yang of idiopathic pulmonary fibrosis
Source: Eur Respir J , 49 (2) 1602316; DOI: 10.1183/13993003.02316-2016
Year: 2017
The of COPD: or balancing repair (yang) and inflammation (yin)
Source: Eur Respir J 2008; 32: 1426-1427
Year: 2008
The yin and yang of immunosuppression with inhaled corticosteroids in asthma and COPD
Source: Virtual Congress 2021 – Pharmacology of lung immune responses: which pathways to target!
Year: 2021
Personalised pathogenetic pathways in fibrotic ILDs: the yin of pathogenetic thinking
Source: International Congress 2019 – Lumping and splitting of fibrotic interstitial lung diseases
Year: 2019
Adenovirus-mediated E2F-1 gene transfer in nonsmall-cell lung cancer induces cell growth arrest and apoptosis
Source: Eur Respir J 2002; 20: 703-709
Year: 2002
Bufei Yishen granules and it combined with acupoint sticking therapy suppresses inflammation in COPD rats: via JNK/p38 signaling pathway
Source: International Congress 2017 – Insight into the pathogenesis of emphysema and pneumonia
Year: 2017
Polymorphisms A1026G and G369C of CDKN1A/p21 and p53 genes in lung cancer
Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics
Year: 2011
Targeting of STAT3 and survivin with TG101209, a novel JAK2 inhibitor, enhances radiotherapy in lung cancer models
Source: Annual Congress 2010 - New insights in the pathology of lung cancer
Year: 2010
Effect of augmentation therapy on immune function of patients with severe Alpha1-antitrypsin deficiency
Source: Annual Congress 2012 - COPD treatments: efficacy and safety
Year: 2012
Does acute phase protein alpha1-antitrypsin modulate apoptosis-autophagy crosstalk resulting in resistance of NSCLC cells to cancer drugs?
Source: Virtual Congress 2021 – Biology of lung cancer: preclinical and translational research
Year: 2021
Diminished expression of HOXA5 in lung cancer
Source: Eur Respir J 2003; 22: Suppl. 45, 256s
Year: 2003
Pathogenetic mechanisms common to disease progression in fibrotic ILDs: the yang of pathogenetic thinking
Source: International Congress 2019 – Lumping and splitting of fibrotic interstitial lung diseases
Year: 2019
Simvastatin overcomes gefitinib resistance in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor via Akt/b-catenin signaling dependent down-regulation of survivin
Source: Annual Congress 2013 –Basic research on lung cancer
Year: 2013
Late Breaking Abstract - Anaplastic Lymphoma Kinase inhibition as an effective treatment strategy against the enhanced lung carcinogenesis and cancer angiogenesis related to decreased PTPRZ1 expression
Source: Virtual Congress 2020 – Biological aspects of lung cancer
Year: 2020
Monoallelic germline ATM mutation and organising pneumonia induced by radiation therapy to the breast
Source: Eur Respir J 2016; 47: 997-1000
Year: 2016
p53 gene mutations in lung cancer in Korean
Source: Eur Respir J 2005; 26: Suppl. 49, 327s
Year: 2005
Novel anti-angiogenic pharmacotherapy strategies
Source: Annual Congress 2005 - Update on the role of angiogenesis in the pathogenesis and treatment of lung diseases
Year: 2005
Anti-angiogenic strategies and vascular targeting in the treatment of lung cancer
Source: Eur Respir J 2002; 19: 557-570
Year: 2002
MicroRNA-101 inhibits lung cancer growth and invasion through regulation of EZH2
Source: Annual Congress 2010 - Pathology of lung cancer
Year: 2010
The role of HER-2/neu, p53, Bcl-2 and Ki-67 in patients with lung cancer
Source: International Congress 2019 – New molecular signatures in COPD, lung cancer and a1-antitrypsin deficiency
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept